Modulation of feeding behavior by central adropin injection in neonatal broiler chicks: evidence for NPY and melanocortin signaling pathways involvement Authors: Golazin Garousi, Samad Alimohammadi, Morteza Zendehdel, Shahin Hassanpour Published: 2026 ABSTRACT BackgroundAdropin, a peptide hormone encoded by the Energy Homeostasis Associated (Enho) gene, is involved in regulating food intake, energy homeostasis, and diverse metabolic functions; it is predominantly produced in the liver and brain and exerts its effects on both central and peripheral tissues.MethodsThis study aimed to evaluate the impact of intracerebroventricular (ICV) adropin administration on food intake and its interactions with NPY and melanocortin systems. This research encompassed 6 experiments organized into 4 distinct groups. In experiment 1, chickens received ICV injections of saline or adropin (0.5, 1, and 2 µg). In experiment 2, birds received ICV injection of saline, B5063 (NPY1 receptor antagonist, 1.25 µg), adropin (2 µg) and co-injection of the B5063 + adropin. Experiments 3 to 6 mirrored the methodology of experiment 2, with the sole modifications being the substitution of B5063 with SF22 (NPY2 receptor antagonist, 1.25 µg), SML0891 (NPY5 receptor antagonist, 1.25 µg), SHU9119 (MC3/MC4 receptor antagonist, 0.5 nmol) and MCL0020 (MC4 receptor antagonist, 0.5 nmol). At 30, 60, and 120 min subsequent to ICV injection, cumulative food intake was evaluated.ResultsAdropin produced a significant reduction in food intake in a dose-responsive manner compared with control animals (p < 0.05). Co-injection of B5063 alongside adropin intensified the hypophagic response elicited by adropin (p < 0.05). Furthermore, the anorexigenic response triggered by adropin was negated when SHU9119 and MCL0020 were given alongside it (p < 0.05). Adropin-mediated suppression of feeding was unaffected by the administration of SF22 and SML0891 (p > 0.05).ConclusionThese findings suggest that the NPY1, MC3, and MC4 receptors contribute to the hypophagic response triggered by adropin. Background Food intake regulation is a physiologically complex process that involves an intricate interaction between central and peripheral factors. Key brain regions like the hypothalamus and brainstem play crucial roles in integrating peripheral signals that influence appetite and feeding behavior [1]. Maintaining body weight is essential for advanced organisms, especially birds and mammals. It depends on the balance between energy intake and expenditure [2]. Neurotransmitters, peptides, and hormones regulate appetite and energy balance by modulating hunger and satiety signals in the CNS and peripheral organs [3, 4]. Adropin is a peptide hormone produced by the Energy Homeostasis Associated (Enho) gene, mainly synthesized and released by the brain and liver, and first identified in 2008 [5]. Studies have demonstrated that adropin is a conserved peptide across multiple vertebrate species, including human, mouse, rat, pig and fish. In addition to its predominant expression in the liver and brain, adropin has been detected in various tissues, such as heart, muscles, kidney, lung, gastrointestinal tract, and circulatory system [6, 7]. The diverse array of biological functions executed by adropin is facilitated through direct engagement with a class A orphan G protein-coupled receptor (GPCR), particularly GPR19 [8, 9]. Adropin contributes to the regulation of key physiological and pathophysiological processes, notably body weight, glucose homeostasis, lipid metabolism, and cardiovascular function [5, 10–12]. Importantly, it acts as a nutritionally regulated peptide hormone that modulates systemic energy balance, improves insulin sensitivity, and reduces hepatic glucose production, thereby alleviating insulin resistance. Adropin also enhances metabolic flexibility by shifting fuel utilization toward glucose oxidation and away from fatty acid oxidation, particularly in cardiac and metabolic tissues. Through these mechanisms, adropin serves as a critical endocrine link between nutritional status, energy expenditure, and metabolic adaptation [5, 13]. Adropin exerts neuroprotective actions against cognitive impairment and neurodegeneration, and central administration enhances spatial memory performance [14, 15]. Furthermore, numerous research efforts have elucidated the considerable influence of adropin concerning the modulation of food intake and appetite control. For instance, a decline in food intake was observed in mice treated with adropin upon intraperitoneal injection [5]. Likewise, following ICV injection of adropin, the water drinking was inhibited in rats [8]. Neuropeptide Y (NPY) is a widely distributed hypothalamic neuropeptide in the central and peripheral nervous systems that regulates feeding behavior and energy homeostasis [16]. The most abundant NPY innervation in the hypothalamus, which extends to nearly the entire region, originates from the arcuate nucleus (ARC) [17]. NPY is a potent orexigenic factor whose various physiological actions occur through interaction with NPY receptors, which are members of the GPCRs family [18]. In recent years, six distinct receptor subtypes for NPY have been elucidated and cloned across various avian tissues [19]. Activation of NPY1, NPY2, and NPY5 receptors underlies NPY-driven modulation of feeding behavior and energy expenditure [20, 21]. In this context, the hyperphagic response induced by ICV injection of NPY has been demonstrated in various species including mice [22], rats [23], and chicks [24]. The melanocortin signaling system is a network of peptides, receptors, and accessory proteins that regulate diverse physiological processes and are actively explored for therapeutic potential [25]. Melanocortin peptides, including ACTH and distinct isoforms of melanocyte-stimulating hormones (α-, β-, and γ-MSH), are predominantly synthesized from the proopiomelanocortin (POMC) gene [26]. To date, five distinct GPCRs, specifically the melanocortin receptors (MC1R-MC5R), have been recognized, which are localized within the CNS as well as in various peripheral tissues [27]. The two aforementioned melanocortin receptors, MC3R and MC4R play crucial roles in controlling feeding behavior and energy use in both birds [28] and rodent models [29], acting primarily within specific hypothalamic nuclei. For example, an injection of melanotan-II (MT-II), a synthetic MC3R/MC4R agonist, resulted in attenuation of food intake in both broiler and layer chicken strains [30]. Moreover, centrally delivered α-MSH has been demonstrated to suppress feeding in neonatal chicks [31]. A functional interplay seems to exist among adropin, NPY, and melanocortin receptors, where these components collectively influence the regulation of food intake. In this regard, adropin may exert an indirect influence on biological pathways that coincide with the metabolic effects mediated by NPY, potentially via signaling mechanisms within the autonomic or CNS [32, 33]. Additionally, adropin interacts with the melanocortin system, whereby a deficiency in MC3R results in a reduction of Enho mRNA expression [5]. Recently, it has been found that adropin exerts an orexigenic effect in fish. Specifically, the appetite-promoting actions of adropin-b appear to be associated with increased expression of the orexigenic genes NPY, Orexin, and Proapelin, accompanied by inhibition of the mRNA levels of anorexigenic POMC and cocaine-amphetamine-regulated transcript (CART) [7]. Based on findings from previous studies, there are no reports addressing the role of adropin in avian species despite notable differences between birds and mammals in the central regulation of food intake. In the current investigation, neonatal broiler chicks were selected for study. The initial days following hatching represent a crucial developmental phase characterized by accelerated growth, elevated protein synthesis, and vigorous organ maturation, thereby rendering the neonatal stage particularly significant for assessing interventions that may influence subsequent health and performance. Moreover, broiler chicks serve as a highly pertinent and well-established model in the field of poultry science owing to their rapid growth rate, convenient handling, and applicability to commercial poultry production. Therefore, the purpose of this novel study was to determine how ICV administration of adropin affects food consumption in neonatal broiler chicks, focusing on its relationship with NPY and melanocortin receptors in appetite control. Materials and methods The various phases of the experimental procedures have been illustrated in Fig. 1. Fig. 1Schematic representation illustrating the experimental procedures Schematic representation illustrating the experimental procedures Animals This trial incorporated 264 male Ross-308 broiler chicks at one day of age into its experimental design. Avian subjects were acquired from Morghak Company’s regional hatchery in Tehran, Iran. Initially, the chicks were kept in groups for 2 days. After that, they were randomly placed into individual cages and maintained under controlled conditions, including a temperature of 30 ± 1 °C, relative humidity of 50 ± 2%, and a photoperiod of 23 h light:1 h dark. Chickens had unrestricted access to fresh water and were provided a starter ration (21% CP, 2850 kcal/kg ME) supplied by Chineh Company, Tehran, Iran (see Table 1). Prior to the ICV injections, the chickens underwent food deprivation for three hours (FD3), while water remained available ad libitum. We launched the studies right after the chicks turned 5 days old [34, 35]. All experiments and animal care practices in this research were authorized by the Animal Ethics Committee at Razi University (Approval No. IR.RAZI.REC.1402.029) and were strictly executed in line with the Guidelines for the Care and Use of Laboratory Animals in Scientific Research [36]. Table 1Characterization of ingredients and nutrient composition of the experimental dietIngredient (%)Nutrient analysisCorn52.85ME (kcal/kg)2850Soybean meal, 48% CP31.57Crude protein (%)21Wheat5Linoleic acid (%)1.69Gluten meal, 61% CP2.50Crude fiber (%)3.55Wheat bran2.47Calcium (%)1Di-calcium phosphate1.92Available phosphorus (%)0.5Oyster shell1.23Sodium (%)0.15Soybean oil1.00Potassium (%)0.96Mineral premix0.25Chlorine (%)0.17Vitamin premix0.25Choline (%)1.30Sodium bicarbonate0.21Arginine (%)1.14Sodium chloride0.20Isoleucine (%)0.73Acidifier0.15Lysine (%)1.21DL-Methionine0.10Methionine (%)0.49Toxin binder0.10Methionine+Cystine (%)0.83L-Lysine HCl0.05Threonine (%)0.70Vitamin D30.1Tryptophan (%)0.20Multi enzyme0.05Valine (%)0.78ME Metabolizable Energy, CP Crude Protein Table 1Characterization of ingredients and nutrient composition of the experimental dietIngredient (%)Nutrient analysisCorn52.85ME (kcal/kg)2850Soybean meal, 48% CP31.57Crude protein (%)21Wheat5Linoleic acid (%)1.69Gluten meal, 61% CP2.50Crude fiber (%)3.55Wheat bran2.47Calcium (%)1Di-calcium phosphate1.92Available phosphorus (%)0.5Oyster shell1.23Sodium (%)0.15Soybean oil1.00Potassium (%)0.96Mineral premix0.25Chlorine (%)0.17Vitamin premix0.25Choline (%)1.30Sodium bicarbonate0.21Arginine (%)1.14Sodium chloride0.20Isoleucine (%)0.73Acidifier0.15Lysine (%)1.21DL-Methionine0.10Methionine (%)0.49Toxin binder0.10Methionine+Cystine (%)0.83L-Lysine HCl0.05Threonine (%)0.70Vitamin D30.1Tryptophan (%)0.20Multi enzyme0.05Valine (%)0.78ME Metabolizable Energy, CP Crude Protein Characterization of ingredients and nutrient composition of the experimental diet ME Metabolizable Energy, CP Crude Protein Experimental drugs The following compounds were purchased from Sigma Co. (Sigma, Saint Louis, MO): adropin, B5063 (specific NPY1 receptor antagonist), SF22 (specific NPY2 receptor antagonist), SML0891 (specific NPY5 receptor antagonist), SHU9119 (non-specific MC3/MC4 receptor antagonist), MCL0020 (specific MC4 receptor antagonist), and Evans Blue. For administration, the pharmacological agents were prepared by dissolving them in a solution composed of 0.1% Evans Blue. This dye solution was obtained by mixing Evans Blue with 0.85% saline in a 1:250 ratio. A blend of saline and Evans Blue dye served as the treatment for the control group. Procedure for ICV drug application The weight of each chick was measured before the start of treatments, and then they were assigned to various experimental groups according to their recorded body weight (BW). The allocation of chicks into treatment groups was conducted to achieve a balanced design, ensuring that the average body weight across all treatment groups was approximately equal. The administration of ICV injections was carried out using a microsyringe (Hamilton, Switzerland) without anesthesia, following established protocols from previous studies [37, 38]. The procedure was conducted by securing the chick’s head in an acrylic fixation device, aligning the bill holder at a 45° inclination and ensuring the calvarium remained parallel to the table surface [39]. A hole was made in a plate positioned above the right lateral ventricle. The microsyringe was advanced via the hole into the ventricle, needle tip 4 mm below the skull surface, and the test solution injected [40]. Saline or drug solution (10 µL) was administered per chick. This method of injection induces no physiological stress in newborn chicks [41]. At the end of the experiment, immediately following the final food intake measurement at 120 min post-ICV injection, chicks were humanely euthanized with an intraperitoneal overdose of sodium thiopental (50 mg/kg; Rotexmedica, Germany) to also verify the accuracy of the ICV injection. This method complies with the AVMA Guidelines for the Euthanasia of Animals (No: S5.2.1.1) and is considered an acceptable non-inhalation euthanasia technique [35, 42]. Decapitation at the study’s conclusion confirmed injection accuracy, as evidenced by Evans Blue in the target site. All experimental procedures were conducted between 8:00 am and 3:30 pm during the course of the study [35, 43]. Feeding experiments As shown in Table 2, a series of 6 independent experiments was carried out in this investigation, each incorporating the 4 treatment groups. A minimum of 11 newborn chicks was allocated to every group, totaling 44 chicks across each trial. Experiment 1 was conducted to assess how ICV administration of adropin at doses of 0.5, 1 and 2 µg affects food intake in FD3 neonatal broiler chickens. During experiment 2, chicks were administered ICV injections consisting of saline, B5063 (1.25 µg), adropin (2 µg), or a combined treatment of B5063 and adropin. In the third experiment, chicks were given ICV injections containing either saline, SF22 (1.25 µg), adropin (2 µg), or both SF22 and adropin together. For experiment 4, researchers administered ICV injections to chicks with one of four treatments: saline, SML0891 (1.25 µg), adropin (2 µg), or a combined preparation of SML0891 and adropin. For experiment 5, researchers delivered ICV injections to chicks with four formulations-saline, SHU9119 (0.5 nmol), adropin (2 µg), and a combined preparation of SHU9119 and adropin. For the sixth experimental trial, chickens were given ICV injections that included saline, MCL0020 (0.5 nmol), adropin (2 µg), or a joint formulation consisting of MCL0020 and adropin. Upon completion of the ICV injection procedure, the chicks were promptly returned to their individual cages. Fresh water and food were provided, and the cumulative food intake (quantified in grams) was meticulously documented at intervals of 30, 60, and 120 min subsequent to the injection. The food intake was adjusted by representing it as a percentage of body weight to minimize the influence of variations in chick weight on their food consumption. Each chick was assigned to only one experimental group and was included solely in food intake measurements at 30, 60, and 120 min after ICV injection; in other words, no chick was reused across different treatments or groups. The various experimental doses of the pharmacological agents delivered via ICV injection, along with the timing of food intake measurement, were determined based on previous research [7, 34, 35, 44] and unpublished pilot studies. Table 2Overview of treatment protocols employed in experiments 1–6ExperimentsGroupsABCD123456Control SolutionControl SolutionControl SolutionControl SolutionControl SolutionControl SolutionAdropin (0.5 µg)B5063 (1.25 µg)SF22 (1.25 µg)SML0891 (1.25 µg)SHU9119 (0.5 nmol)MCL0020 (0.5 nmol)Adropin (1 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)B5063 + AdropinSF22 + AdropinSML0891 + AdropinSHU9119 + AdropinMCL0020 + Adropin Table 2Overview of treatment protocols employed in experiments 1–6ExperimentsGroupsABCD123456Control SolutionControl SolutionControl SolutionControl SolutionControl SolutionControl SolutionAdropin (0.5 µg)B5063 (1.25 µg)SF22 (1.25 µg)SML0891 (1.25 µg)SHU9119 (0.5 nmol)MCL0020 (0.5 nmol)Adropin (1 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)Adropin (2 µg)B5063 + AdropinSF22 + AdropinSML0891 + AdropinSHU9119 + AdropinMCL0020 + Adropin Overview of treatment protocols employed in experiments 1–6 1 2 3 4 5 6 Control Solution Control Solution Control Solution Control Solution Control Solution Control Solution Adropin (0.5 µg) B5063 (1.25 µg) SF22 (1.25 µg) SML0891 (1.25 µg) SHU9119 (0.5 nmol) MCL0020 (0.5 nmol) Adropin (1 µg) Adropin (2 µg) Adropin (2 µg) Adropin (2 µg) Adropin (2 µg) Adropin (2 µg) Adropin (2 µg) B5063 + Adropin SF22 + Adropin SML0891 + Adropin SHU9119 + Adropin MCL0020 + Adropin Statistical analysis Results are expressed as mean ± standard error of the mean (SEM) and were analyzed through a 2-way repeated measures analysis of variance (ANOVA) using the SPSS software version 21 for Windows (SPSS, Inc., Chicago, IL). In cases where a significant treatment effect was detected by the ANOVA, the Tukey-Kramer post hoc test was applied to compare the means between groups. A threshold of p < 0.05 was established to determine whether differences between treatments were statistically significant. Results According to Fig. 2, comparison between the 0.5 µg adropin treatment and the control group revealed no significant difference (p > 0.05). A notable dose-dependent suppression of food consumption was detected following ICV injection of adropin (1 and 2 µg) relative to the control group, persisting over the full 120-min monitoring period in FD3 chicks (p < 0.05). Based on Fig. 3, no significant variation in food intake was observed between the B5063-treated group (1.25 µg, ICV) and the control group (p > 0.05). FD3 chickens receiving an ICV infusion of adropin (2 µg) exhibited a significant decrease in food intake at 30, 60, and 120 min post-treatment compared to controls (p < 0.05). The coinjection of the B5063 with effective dose of adropin markedly enhanced the hypophagic response elicited by adropin (p < 0.05). As seen in Fig. 4, no notable differences in food intake were observed between the SF22-treated group (1.25 µg, ICV) and the control group (p > 0.05). ICV administration of adropin (2 µg) induced significant hypophagia in FD3 chickens relative to controls (p < 0.05). The coinjection of SF22 + adropin did not produce any significant change in the hypophagic effect induced by adropin alone (p > 0.05). As observed in Fig. 5, ICV delivery of SML0891 (1.25 µg) did not lead to any significant change in feeding response versus the control group (p > 0.05). A 2 µg dose of adropin led to reduced food intake in FD3 chickens compared to control birds (p < 0.05). In contrast, ICV infusion of the SML0891 failed to reverse adropin-mediated hypophagia (p > 0.05). According to Fig. 6, administration of SHU9119 (0.5 nmol) via ICV injection alone did not elicit any significant impact in the food intake compared to the control group (p > 0.05). The administration of adropin (2 µg) effectively suppressed food intake compared to the control group in FD3 chickens (p < 0.05). The coinjection of the SHU9119 + adropin weakened hypophagia induced by effective dose of adropin (p < 0.05). As seen in Fig. 7, ICV delivery of MCL0020 at a dose of 0.5 nmol did not elicit any significant modification in feeding behavior relative to controls (p > 0.05). The suppressive influence of adropin (2 µg) on food intake was noted subsequent to central administration in comparison to control birds in FD3 chickens (p < 0.05). Giving MCL0020 together with the effective adropin dose lessened adropin’s inhibitory action on food intake (p < 0.05). Fig. 2Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution or adropin at doses of 0.5, 1, and 2 µg (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution or adropin at doses of 0.5, 1, and 2 µg (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Fig. 3Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, B5063 (NPY1 receptor antagonist, 1.25 µg), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, B5063 (NPY1 receptor antagonist, 1.25 µg), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Fig. 4Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, SF22 (NPY2 receptor antagonist, 1.25 µg), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b) differ significantly from one another at each time point (P < 0.05) Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, SF22 (NPY2 receptor antagonist, 1.25 µg), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b) differ significantly from one another at each time point (P < 0.05) Fig. 5Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, SML0891 (NPY5 receptor antagonist, 1.25 µg), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b) differ significantly from one another at each time point (P < 0.05) Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, SML0891 (NPY5 receptor antagonist, 1.25 µg), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b) differ significantly from one another at each time point (P < 0.05) Fig. 6Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, SHU9119 (nonselective MC3/MC4 receptor antagonist, 0.5 nmol), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, SHU9119 (nonselective MC3/MC4 receptor antagonist, 0.5 nmol), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Fig. 7Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, MCL0020 (selective MC4 receptor antagonist, 0.5 nmol), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Cumulative food intake (gr/100gr BW) in neonatal broiler chicks following ICV infusion of control solution, MCL0020 (selective MC4 receptor antagonist, 0.5 nmol), adropin (2 µg), and co-administration of both agents (n = 11 per group). Values are presented as mean ± SEM. Treatments labeled with different letters (a, b, c) differ significantly from one another at each time point (P < 0.05) Discussion This novel investigation reveals for the first time that ICV adropin affects feeding in neonatal broiler chicks by interacting with NPY and melanocortin receptors. Broiler feeding behavior, energy expenditure, and body weight are regulated by coordinated brain-peripheral hormone signals, revealing mechanisms to improve broiler farming and production outcomes [2]. Feed efficiency in livestock is considered a key factor for sustainably increasing animal protein production, as improved nutrient utilization and productivity are achieved while environmental impact is reduced [45]. A comprehensive insight into these control processes is particularly crucial for poultry production. This study found that ICV infusion of adropin dose-dependently inhibited cumulative food intake in neonatal broilers, pointing to adropin’s possible role as a central anorexigenic agent in these chicks. Adropin controls feeding and energy balance and is highly expressed in CNS brain regions, especially hypothalamic nuclei [46]. Consistent with the current study, intraperitoneal adropin reduced mouse food intake in a dose-dependent manner, lowering body weight without altering physical activity [5]. In addition, our results support previous findings that central adropin reduces feed intake in broilers, demonstrating a comparable inhibitory action on feeding behavior as observed in this study [44]. The exact mechanisms through which adropin decreases eating behavior have not yet been completely clarified. Earlier research has documented that adropin elicits its central biological actions by binding to GPR19, which subsequently initiates phosphorylation-dependent activation of ERK and Akt signaling pathways, integrating extracellular peptide signals into intracellular responses that regulate neuronal and metabolic functions in the brain [8]. The hypothalamic PVN is a central site where adropin exerts its physiological effects related to fluid homeostasis and energy balance through direct neuronal modulation [45]. On the other hand, the GPR19-dependent actions of adropin in the PVN likely underpin its role in influencing TRH secretion and downstream energy homeostasis mechanisms, highlighting a critical neuroendocrine interface for metabolic regulation [47]. Moreover, adropin’s central nervous effects are mediated either by activating transient receptor potential cation channels to decrease water intake in rats [48] or by binding to the brain-specific Notch1 ligand NB3 to control brain development in mice [49]. The paramount contribution of the present investigation was the clarification of the precise receptor mechanisms implicated in adropin-induced hypophagia. As delineated in our study, the concurrent administration of B5063 (NPY1 receptor antagonist) and adropin augmented the hypophagic response elicited by adropin. Nevertheless, when adropin was co-administered with SF22 (NPY2 receptor antagonist) and SML0891 (NPY5 receptor antagonist) in neonatal broiler chicks, it showed no interplay with these NPY receptors in modulating food intake. The NPY-positive neurons within the hypothalamic arcuate nucleus serve as pivotal mediators in appetitive behavior and energy homeostasis, exerting potent orexigenic effects via various receptor subtypes [50]. Central NPY injection markedly increases food intake in both broiler and layer chicken strains [51]. In the present study, the lowest dose of the B5063 (1.25 µg, ICV) did not alter food intake when administered alone. This outcome is consistent with prior evidence demonstrating that this dose is sub-effective in avian models and does not produce measurable changes in feeding behavior [21, 34]. Accordingly, the absence of an effect at this dose likely reflects insufficient functional blockade of Y1 receptor signaling rather than a lack of involvement of the NPY-Y1 pathway in the regulation of food intake. The ICV infusion of B5063 and SML0891 (at doses of 2.5 and 5 µg) resulted in a significant decrease in food intake, which was found to be proportional to the administered dosage. Conversely, the application of a NPY2 receptor blocker was associated with an augmentation in the quantity of feed ingested by broiler chickens [21]. It has been noted that hypophagia from adrenomedullin in layer strain neonatal chicks occurs via the NPY1 receptor signaling pathway [34]. There are currently no reports or data on the relationship between adropin and NPY receptors in the central regulation of feeding behavior in birds; this study presents the first such findings. These results offer a solid foundation for future research exploring how adropin influences the control of food intake in poultry. A key result identified in this research revealed that when SHU9119 (MC3/MC4 receptor antagonist) was given alongside adropin, it counteracted the decline in food consumption caused by adropin in neonatal broiler chicks. Furthermore, simultaneous administration of MCL0020 (MC4 receptor antagonist) with adropin attenuated anorexigenic action of adropin. The melanocortin system’s involvement in appetite regulation, characterized by a significant inhibitory influence, is indisputable. In particular, MC3 and MC4 receptors within this system crucially modulate meal patterns and intake [52, 53]. There may be neuroendocrine crosstalk between the central melanocortinergic pathway and hormones that control food intake and energy balance. For instance, pharmacological findings from our previous study demonstrated that spexin’s ability to reduce food intake is partially facilitated through the engagement of MC3/MC4 receptors within the central melanocortinergic circuits [35]. Additionally, adropin interacts with the melanocortin system, as evidenced by reduced Enho mRNA expression-the gene encoding adropin-in conditions of MC3R deficiency [5]. Given the paucity of data on chicks, contextualizing our findings against prior research is constrained. Moreover, insufficient studies preclude definitive characterization of adropin-MC3R/MC4R interactions in food intake regulation. Conclusion In summary, this study for the first time confirms that central adropin acts as a powerful anorectic mediator in neonatal broiler poultry, functioning via highly selective interactions with NPY1 and MC3/MC4 receptors. This finding suggests a previously unappreciated complexity in the regulation of appetite control in birds and provides indirect, pharmacological evidence of pathway involvement. Future investigations employing avian-specific adropin peptides, along with detailed receptor homology analyses, will be essential to fully validate ligand-receptor interactions in birds. Moreover, given the limited number of studies addressing the physiological roles of adropin, particularly in avian species, further research incorporating advanced cellular and molecular approaches, as well as neuroimaging techniques, is warranted to elucidate the multifaceted functions of this peptide hormone. Limitations of the study This study has several important limitations that should be considered when interpreting the results. First, the findings provide only indirect, pharmacological evidence of pathway involvement and do not constitute definitive mechanistic proof. The results rely entirely on the use of receptor antagonists, and no direct measurements of receptor activity were performed. Additionally, we did not assess gene expression of key neuropeptides and receptors (NPY, POMC, and MC receptors), nor did we evaluate downstream signaling events associated with pathway activation. Another limitation is that water intake was not measured in the chicks used in this study.